Scoping to analyze oncology trial participation in Australia

IF 3 3区医学 Q2 ONCOLOGY

Seminars in oncology Pub Date : 2022-04-01 DOI:10.1053/j.seminoncol.2022.04.003

Kyung Ha You , Elizabeth Ahern , David Wyld , Zarnie Lwin , Natasha Roberts

{"title":"Scoping to analyze oncology trial participation in Australia","authors":"Kyung Ha You , Elizabeth Ahern , David Wyld , Zarnie Lwin , Natasha Roberts","doi":"10.1053/j.seminoncol.2022.04.003","DOIUrl":null,"url":null,"abstract":"<div><p>Equity in oncology clinical trial participation has been declared a global priority. Australia is a key stakeholder in the global clinical trials sphere and managed to maintain high clinical trial activity during the COVID pandemic. Despite these successes, there is paucity of understanding about what influences clinical trial participation in Australia. In the international context, systematic reviews have highlighted that sociodemographic barriers, access to health care, clinical trial inclusion criteria, and attitudes of physicians and patients are factors which influence oncology trial participation. Exploring the factors in Australian health services which influence trial participation is now of significant importance. The lack of clear evidence directly highlights a need to assess the factors that influence oncology trial participation in Australia. We call for review of existing data to identify future directions in Australia which will potentially give deeper insights for the international clinical trial community.</p></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"49 2","pages":"Pages 178-181"},"PeriodicalIF":3.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S009377542200029X/pdfft?md5=3092de07930fd3ea862af5b29d907801&pid=1-s2.0-S009377542200029X-main.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S009377542200029X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Equity in oncology clinical trial participation has been declared a global priority. Australia is a key stakeholder in the global clinical trials sphere and managed to maintain high clinical trial activity during the COVID pandemic. Despite these successes, there is paucity of understanding about what influences clinical trial participation in Australia. In the international context, systematic reviews have highlighted that sociodemographic barriers, access to health care, clinical trial inclusion criteria, and attitudes of physicians and patients are factors which influence oncology trial participation. Exploring the factors in Australian health services which influence trial participation is now of significant importance. The lack of clear evidence directly highlights a need to assess the factors that influence oncology trial participation in Australia. We call for review of existing data to identify future directions in Australia which will potentially give deeper insights for the international clinical trial community.

查看原文本刊更多论文

分析澳大利亚肿瘤试验参与情况的范围

肿瘤学临床试验参与的公平性已被宣布为全球优先事项。澳大利亚是全球临床试验领域的关键利益攸关方，并在COVID大流行期间保持了较高的临床试验活动。尽管取得了这些成功，但人们对影响澳大利亚临床试验参与的因素缺乏了解。在国际背景下，系统评价强调，社会人口学障碍、获得卫生保健、临床试验纳入标准以及医生和患者的态度是影响肿瘤试验参与的因素。探索澳大利亚保健服务中影响参与试验的因素现在具有重要意义。缺乏明确的证据直接突出了评估影响澳大利亚肿瘤试验参与的因素的必要性。我们呼吁对现有数据进行审查，以确定澳大利亚的未来方向，这可能会为国际临床试验界提供更深入的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in oncology 医学-肿瘤学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

104 days

期刊介绍： Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.